Pricing Log in Create free account
Saturday 17 October 2026 Export PRCT’s income statement to Excel — free account

PROCEPT BioRobotics Corporation

PRCT Healthcare Medical Devices

PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024. In the quarter to June 2026, revenue grew 19.3%, EPS fell 34.3%, free cash flow fell 24.4% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.

17.57 0.58 −3.20%
Market cap
$1.0B
P/E
0.0×
Fwd P/E
−18.2×
Dividend yield
—
F-score
5/9
Altman Z
6.44
Beneish M
−2.86
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 10.98
Total sells 0.62
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — 1 — — — — 1 — —
Sell — — — — 6 — — 3 — — 3 —
Insider Ownership 4.29%

Capital & Financial Ratios $m

Market Cap 1,040.00
Revenue 337.34
Net Income (109.75)
Free Cash Flow (84.92)
Net Debt (176.20)
Current Ratio 6.55 (at or above 1.5: strong)
Debt/Equity 0.15 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (18.20) (negative: loss-making)
P/S ratio 2.97
P/B ratio 2.95
Past 5Y EPS Growth —
This Y EPS Growth 2.77%
Next Y EPS Growth 31.13% (at or above 15%: strong)
Next Y revenue growth 28.32% (at or above 10%: strong)
Next 5Y EPS Growth 21.44% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 2.5×, against a ten-year median of 14.0×; over the ten years it ranged from 1.6× in 2022 to 35.8× in 2022.
P/S against its own 10 years 0.79%
10-year low 10-year high
P/B against its own 10 years 10.73%
10-year low 10-year high
EV/Sales against its own 10 years 3.16%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 257 334 287 228
Receivables 48 83 84 108
Inventory 40 56 71 77
Other — — — —
351 482 450 420
2023 2024 2025 Q'26
Payables 13 10 17 15
ST’ Debt 2 2 — —
Other 6 8 10 12
46 53 66 64

Compound Annual Growth %

10y 5y 3y
Sales — 109.04% 60.14%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 43.11% 22.90%

Revenue $m

Mar Jun Sep Dec Year
’26 83 94 — — —
’25 69 79 83 76 308
’24 45 53 58 68 224
’23 24 33 35 44 136
’22 14 17 20 24 75
’21 7 8 9 10 34
’20 — — 2 — 8
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (38) (19) — — —
’25 (17) (15) (7) (10) (49)
’24 (32) (16) (19) (32) (99)
’23 (36) (28) (19) (25) (108)
’22 (18) (17) (20) (25) (80)
’21 (15) (13) (13) (16) (57)
’20 — — (35) (13) (48)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (41) (22) — — —
’25 (19) (18) (10) (12) (58)
’24 (34) (17) (19) (34) (104)
’23 (41) (34) (25) (34) (133)
’22 (18) (17) (21) (26) (83)
’21 (15) (13) (13) (17) (58)
’20 — — (35) (13) (49)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.56) (0.47) — — —
’25 (0.45) (0.35) (0.38) (0.53) (1.72)
’24 (0.51) (0.50) (0.40) (0.35) (1.75)
’23 (0.63) (0.56) (0.51) (0.54) (2.24)
’22 (0.39) (0.43) (0.51) (0.63) (1.96)
’21 (2.65) (2.60) (1.22) (0.42) (3.63)
’20 — — (2.77) — (14.47)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

2.5
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — 24.20 15.38 24.83 39.48 27.80

Analyst estimates 2026–2028

Powerpack
High — — — — — 47.73 52.40 43.90 103.81 89.49
People
People Employees — — — — 205 234 428 626 756 888
Revenue/emp, $m — — — 0.00 0.04 0.15 0.18 0.22 0.30 0.35
Income, $m
Income, $m Revenue — — — 6 8 34 75 136 224 308
Gross margin, % — — — (30.56) (16.26) 46.02 49.44 52.17 61.07 63.70
EBT — — — (42) (53) (60) (87) (106) (91) (95)
EBT margin, % — — — (680.42) (687.04) (173.62) (116.18) (77.70) (40.55) (30.96)
Net income — 0 — (42) (53) (60) (87) (106) (91) (96)
Depreciation — — — 1 3 3 3 4 5 6
Per share, $
Per share, $ Revenue — — — 0.14 2.11 2.09 1.69 2.88 4.31 5.55
Earnings — — — (0.97) (14.47) (3.63) (1.96) (2.24) (1.75) (1.72)
Cash flow — — — (1.01) (13.20) (3.48) (1.81) (2.29) (1.90) (0.88)
Capex — — — 0.00 (0.06) (0.04) (0.06) (0.53) (0.08) (0.17)
Free cash flow — — — (1.01) (13.26) (3.51) (1.87) (2.82) (1.99) (1.05)
Book value — — — 0.68 16.64 16.21 4.44 5.94 7.72 6.59
Shares, m — — — 43 4 16 44 47 52 56
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 0.00 0.00 11.96 23.42 14.38 18.70 5.67
P/B — — — 0.00 0.00 1.54 8.91 6.98 10.43 4.78
EV/Sales — — — 0.00 0.00 4.68 21.18 12.88 17.45 4.92
EV/FCF — — — (1.69) (1.69) (2.79) (19.14) (13.17) (37.80) (25.96)
Cash, $m
Cash, $m Operating cash flow — — — (44) (48) (57) (80) (108) (99) (49)
Capex — — — (8) 0 (1) (3) (25) (4) (9)
Free cash flow — — — (44) (49) (58) (83) (133) (104) (58)
Balance, $m
Balance, $m Working capital — — — 44 96 310 237 305 429 385
Total debt — — — 23 52 54 55 53 53 52
Net debt — — — (19) (48) (251) (168) (204) (280) (235)
Shareholders’ equity — — — 29 61 267 197 281 402 366
Returns, %
Returns, % ROA — — — (135.41) (56.41) (25.85) (26.97) (29.66) (19.48) (18.34)
ROIC — — — 0.00 (225.01) (206.72) (170.70) (88.89) (49.51) (49.56)
ROE — — — 25.69 32.45 (142.17) (37.55) (44.32) (26.77) (24.89)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

PROCEPT BioRobotics Corporation vs peers in Medical Devices (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
TNDM Tandem Diabetes Care, Inc. $1.2B — (loss-making) — (loss-making) +5.77% (above 0%: growing) n/m −146.34% (below 0%: shrinking) 56.87% (5.42%) Compare
IRMD iRadimed Corporation $1.1B 48.5× 48.7× +0.28% (above 0%: growing) −8.89% (below 0%: shrinking) +11.66% (above 0%: growing) 74.07% 31.23% Compare
ENOV Enovis Corporation $1.1B — (loss-making) 195× +3.23% (above 0%: growing) n/m +815.79% (above 0%: growing) 61.64% 2.99% Compare
AORT Artivion, Inc. $1.1B — (loss-making) 142× +11.32% (above 0%: growing) n/m −202.47% (below 0%: shrinking) 64.03% (6.65%) Compare
CBLL CeriBell, Inc. $1.1B — (loss-making) — (loss-making) +32.54% (above 0%: growing) n/m −68.63% (below 0%: shrinking) 92.32% (71.11%) Compare
IART Integra LifeSciences Holdings Corporation $1.1B — (loss-making) 26.1× +0.76% (above 0%: growing) n/m +193.48% (above 0%: growing) 52.47% 4.61% Compare
PRCT PROCEPT BioRobotics Corporation $1.0B — (loss-making) — (loss-making) +19.34% (above 0%: growing) n/m −24.43% (below 0%: shrinking) 66.01% (28.98%)
LMRI Lumexa Imaging Holdings, Inc. $1.0B — (loss-making) 14.2× +7.82% (above 0%: growing) n/m +257.54% (above 0%: growing) 14.72% 8.72% Compare
QDEL QuidelOrtho Corporation $953.9M — (loss-making) — (loss-making) +2.77% (above 0%: growing) n/m −61.45% (below 0%: shrinking) 43.26% (3.46%) Compare
Median of peers $1.1B — 48.7× +4.50% — −24.90% 59.25% (0.23%)

All 149 Medical Devices stocks →

PROCEPT BioRobotics Corporation (PRCT) key facts

  • Concern: PROCEPT BioRobotics Corporation reported a net loss of $95.6 million, or a loss of $1.72 per share, for fiscal 2025.
  • Strength: PROCEPT BioRobotics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $308.1 million, up 37.2% from fiscal 2024.
  • PROCEPT BioRobotics Corporation (PRCT) is a Medical Devices company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PRCT traded at $17.57, a market capitalization of $1.0 billion.
  • Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 3.0× sales.
  • Return on equity was −24.9% and debt-to-equity 0.15.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is 6.44 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

PROCEPT BioRobotics Corporation (PRCT) Latest News

23 Mar

Impact 5 ·
stockrow.com/PRCT · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com